🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hopefully you enjoy this as much as we did. An excellent conversation with an esteemed group of amyloidologists, covering many topics that are pertinent to all physicians, healthcare providers and patients. #CardioTwitter

1) Welcome to a new #accredited #tweetorial from @cardiomet_ce, your ONLY source for expert-led #cardiometabolic professional education delivered entirely on X ! We are at the European Society of Cardiology's #HeartFailure2025 congress in #Belgrade. Follow this 🧵for 🆓0.75hrCE/#CME!

An important analysis. Aficamten effect is consistent regardless of symptom severity in obstructive HCM. In a remodeled ventricle with significant limitations in exercise metrics and elevated NTproBNP, symptoms on their own are not really a good metric to decide on starting

Great to see this paper out in JACC Journals Establishing the role of transthyretin (prealbumin) as a surrogate of treatment effect of transthyretin stabilizers in ATTR-CM, such as acoramidis in this particular paper jacc.org/doi/epdf/10.10… #CardioTwitter

Vutrisiran in Helios B trial showed consistent effect across HF severity jacc.org/doi/10.1016/j.… #CardioTwitter

Intriguing new data out in JACC Journals in time for #HeartFailure2025 from ATTRibuteCM Stabilization of TTR (prealbumin) leads to immediate & sustained rise in TTR levels Degree of rise identifies those likely to derive mortality protection from TTR stabilizers #MedIQHF2025

New data from #ATTRibuteCM presented at #HeartFailure2025 Intriguing analysis by Kevin Alexander High-affinity TTR stabilizer acoramidis potentially associated with lower risks of AF/AFL events in #ATTRCM #MedIQHF2025

How do patients with #ATTRCM die? New insights from #ATTRibuteCM at #HeartFailure2025 Kevin Alexander Ahmad Masri #MedIQHF2025

Excellent study linking acoramidis, TTR levels, & mortality in ATTRIBUTE-CM now in JACC Journals Congrats Jessica Regan on leading our accompanying editorial (bit.ly/436F0i0) & 🙏 outstanding collaborators Michelle Kittleson MD PhD Michel Khouri Frederick L Ruberg Duke Heart

3 out of 7 newly diagnosed ATTR-CM patients that I saw in 1 day didnt have ATTR-CM (2 on therapy). Just really tough to interpret PYP scans with blood pooling, and due to cavity size and shape they simply appeared as myocardial uptake to those reading them. That is why we are

Methawasin & colleagues found reducing harmful protein clumps in heart muscle cells with a special molecule called antisense oligonucleotide (#ASO) could help treat #RBM20 cardiomyopathy. Learn more at ahajrnls.org/4k54X7v

Think Amyloidosis ASNC Society Tune in for best practices and imaging update’s #CvNuC

Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy Acoramidis-mediated early ΔTTR is independently associated with improved survival after adjusting for known predictors jacc.org/doi/10.1016/j.…

🔴 Efficacy of Aficamten in Patients with Obstructive HCM & Mild Symptoms: Results from the SEQUIOA-HCM Trial European Society of Cardiology Journals #Cardiology #CardioEd #FOAMed

Thank you to Muthu Vaduganathan for his live updates on ATTR-CM from #HeartFailure2025. Check out this thread for highlights. #Transthyretinamyloidcardiomyopathy #Cardiomyopathy #Amyloidosis #MedIQHF2025

#HeartFailure2025 #LBCT by Marianna Fontana #HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM #MedIQHF2025

Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. Read more in EHJ. doi.org/10.1093/eurhea… @ESCardio European Society of Cardiology Journals #Amyloidosis #AF

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B Consistent with primary trial results, vutrisiran reliably reduced risk of ACM, CV mortality, CV hospitalizations, HFH , and urgent HF visits jacc.org/doi/10.1016/j.…

academic.oup.com/eurheartj/adva… #WhyCMR #Epeeps #Sarcoidosis

Disappointing results However, we need to persistent in the pursuit of therapies for advanced AL. Anselamimab and AT02 trials ongoing ir.prothena.com/investors/pres… #CardioTwitter